IP Library Granted Patent US 11,268,095
Granted Patent B2
US 11,268,095 · App. 16/075,479 · Granted Mar 8, 2022

Treatment and diagnosis of inflammatory disorders

Inventors: Zhenglun Zhu (Newton, MA); Hong Gao (Downingtown, PA)
C12N15/1137A61K31/7115A61K35/17C12N5/0645C12N15/113C12Q1/68C12Q1/6883G01N33/5023G01N33/6875A61P29/00C12N2310/11C12N2310/14C12N2310/3233C12Q2600/158G01N2333/4703G01N2800/52G01N2800/7095
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,268,095
App. No.
16/075,479
Granted
Mar 8, 2022
Kind
B2
Abstract

A method of treating an inflammatory disorder in a subject, comprising administering to the subject in need thereof a nucleic acid molecule for inhibiting the expression of Hom-1. Specifically, the nucleic acid molecule is an RNAi agent or an antisense morpholino oligonucleotide. Further disclosed is a method of selecting a therapeutic for an inflammatory disorder in a subject, or monitoring the efficacy of a therapeutic for an inflammatory disorder in a subject, comprising detecting the expression level of Hom-1 in an inflamed tissue sample obtained from the subject.

Claims (6)

1. A method of treating an inflammatory disorder in a subject in need thereof, comprising:

providing a modified macrophage, monocyte, or dendritic cell that has been treated with a Hom-1 inhibitor or contains an expression construct for expressing a Hom-1 inhibitor, wherein the modified macrophage, monocyte, or dendritic cell expresses a lower level of Hom-1 as compared with a control level, the Hom-1 inhibitor being an RNAi agent or an antisense oligonucleotide; and

administering an effective amount of the modified macrophage, monocyte, or dendritic cell to the subject.

2. The method of claim 1 , wherein the Hom-1 inhibitor inhibits the expression of Hom-1.

3. The method of claim 2 , wherein the Hom-1 inhibitor is a morpholino oligonucleotide.

4. The method of claim 1 , further comprising, prior to the providing step, detecting a higher expression of Hom-1 than a control level in an inflamed tissue sample obtained from the subject.

Continuity (2)
Provisional Application 62291271 · Feb 4, 2016
Related Publication 20190085336A1 · Mar 21, 2019